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ARTICLE
Enhanced validation of antibodies for research
applications
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Åsa Sivertsson1,2, Hanna Tegel 2, Sophia Hober2, Cristina Al-Khalili Szigyarto1,2, Linn Fagerberg 1,2,
Kalle von Feilitzen1,2, Per Oksvold 1,2, Cecilia Lindskog4, Björn Forsström 1,2 & Mathias Uhlen 1,2,5
There is a need for standardized validation methods for antibody speciﬁcity and selectivity.
Recently, ﬁve alternative validation pillars were proposed to explore the speciﬁcity of
research antibodies using methods with no need for prior knowledge about the protein target.
Here, we show that these principles can be used in a streamlined manner for enhanced
validation of research antibodies in Western blot applications. More than 6,000 antibodies
were validated with at least one of these strategies involving orthogonal methods, genetic
knockdown, recombinant expression, independent antibodies, and capture mass spectro-
metry analysis. The results show a path forward for efforts to validate antibodies in an
application-speciﬁc manner suitable for both providers and users.
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There are several challenges that must be overcome tovalidate the speciﬁcity and reproducibility of antibodyreagents and this has been emphasized by many recent
publications1–8. One important issue is cross-reactivity due to off-
target binding, which is deﬁned as antibodies binding to proteins
other than the intended target9. Another issue is that samples are
treated differently in different applications, which inﬂuence the
epitopes exposed on the target protein. As a result, this might
have profound consequences for the ability of a given antibody to
bind speciﬁcally to its target10. Thus, antibodies must be validated
in an application-speciﬁc manner, as was recently pointed out
by the International Working Group for Antibody Validation
(IWGAV)11. The working group proposed ﬁve pillars for anti-
body validation, all allowing the antibody to be validated without
the need for any prior knowledge of the target protein, except the
gene and protein sequence. This is important since many of the
proteins predicted from the genome sequence lack previous lit-
erature and they are thus important targets for antibody-based
studies to allow a genome-wide analysis of the entire human
proteome. Here, we have adapted these pillars for Western blot
applications with a focus on providing scalable and streamlined
methods. We present a strategy for enhanced validation suitable
for commercial providers as well as small sized research groups
with limited resources.
The Western blot application is the most frequently used
antibody-based method12, with approximately 1.5 million anti-
bodies classiﬁed as supported for this application in the Anti-
bodypedia portal13. In a Western blot assay, the approximate size
of the target protein is obtained as part of the analysis and off-
target binding can be probed by the presence or absence of
additional bands. However, many protein bands are shifted in size
compared to the predicted molecular weight, e.g. due to proteo-
lytic processing and various post-translational modiﬁcations,
including glycosylation. Yang et al.14 cataloged such variation by
carrying out proteome-wide quantitative mass spectrometry (MS)
in a vast number of slices from polyacrylamide gels and recon-
structing virtual Western blots that were compared to predicted
molecular weights of unmodiﬁed proteins. Around 15% of the
proteins had their most prominent band far from the predicted
molecular weight and even more had multiple bands that all
mapped to the same protein-coding gene. Consequently, there is
an obvious need for validation principles that are independent
and complementary to the theoretical size estimate used in the
standard Western blot assay.
Here, we show that the methods described can be used for
streamlined validation of antibodies for Western blot applications
using convenient panels of cell lines for the analysis. More than
6,000 antibodies were validated in at least one of the ﬁve methods
and all the primary data for the validation is presented as part of
the Human Protein Atlas (www.proteinatlas.org) antibody info
page for each respective antibody A special focus was to inves-
tigate the performance of the orthogonal and gel-migration
capture MS validation strategies, since there are no prior exam-
ples in the literature of systematic validation of antibodies using
these two rationales. In the orthogonal validation strategy, the
protein abundance levels obtained using an antibody-dependent
method are compared with the levels determined by an antibody-
independent method across a set of samples. For the capture MS
strategy, the apparent size obtained by an antibody is compared
to the presence of MS-determined target peptides after cutting
out gel slices. Altogether 1,630 antibodies were validated by at
least two of the pillars and 267 were validated by three or more
pillars. The results show a path forward for streamlined validation
of antibodies, although it is important to point out that the
enhanced validation is speciﬁc for a certain sample context and
the validation is thus dependent on the sample preparation
procedures used to evaluate the assay including the relative
abundance of the target protein.
Results
Orthogonal validation of antibodies using proteomics. More
than 6,000 antibodies were validated in at least one of the ﬁve
methods and all the primary data for the validation is presented
as part of the Human Protein Atlas (www.proteinatlas.org)
antibody info page for each respective antibody (Supplementary
Data 1). In Fig. 1, a description of the ﬁve validation methods
adapted for validation of research antibodies in Western blot
applications are outlined including a summary of the features and
limitations of each strategy. For orthogonal validation, the protein
levels determined by an antibody-dependent method are com-
pared with the levels determined by an antibody-independent
method across a panel of samples. Here, we decided to use a panel
of cell lines (Fig. 2a) to allow for protein expression analysis with
the aim to establish a platform for validation that could be easily
reproduced by both users and providers of antibodies. We deci-
ded to select cell lines (Supplementary Table 1) from a list of 56
cell lines (Supplementary Fig. 1) showing highly variable gene
expression levels based on genome-wide transcriptomics analysis
Orthogonal strategies Independent antibody
strategies Genetic strategies Capture MS
Recombinant
expression strategies
Strategy
Description
Throughput
Comparison with ab-
independent method
Matched staining from
two antibodies
Decreased levels of
target protein
Increased levels of
target protein
Size comparison using
mass spectrometry
Limitations
Need differential
expression of target
protein
Need antibodies with
different epitopes
Need functional knock-
down reagents
Need functional
expression clone
Many proteins have
similar size
+++ ++ + + +++
Specificity Variable ++ +++ ++ +
Fig. 1 Advantages and disadvantages of the ﬁve strategies used for enhanced Western blot antibody validation. Throughput is a relative estimate of the
possibility to use the method for high-throughput settings and speciﬁcity is the estimate of how reliable the validation results are to determine the
speciﬁcity of the antibody. Low: +, Medium: ++, High: +++
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(Supplementary Data 2). The analysis of the human cell lines
demonstrates that a majority (n= 14,622) of all the protein-
coding genes (n= 19,628) have a relatively high RNA expression
(TPM value > 10) in at least one of the cell lines.
We ﬁrst explored the possibility to validate antibodies for
Western blot application by orthogonal validation using a cell line
panel quantitatively measured by MS-based proteomics, either by
an unbiased tandem mass tag (TMT) 10plex shotgun strategy15 or
by a target proteomics Parallel Reaction Monitoring (PRM)
strategy (Supplementary Data 3-4). The Western blot bands for
each antibody could thus be evaluated by correlating the band
intensities with the proteomics results (Supplementary Data 5).
For the TMT-based proteomics analysis, 23 antibodies towards 22
protein targets were analyzed, including seven membrane-bound
proteins, while 33 antibodies towards 29 protein targets were
analyzed and quantiﬁed using a targeted proteomics approach
(PRM) with internal standard spike-in. In Fig. 2b, the results
using two antibodies towards a histamine N-methyltransferase
(HNMT) are shown for the targeted proteomics approach (PRM)
demonstrating high correlation with the levels determined by
Western blot band analysis for antibody 1, while the second
antibody shows one band of similar size, but no correlation with
the proteomics results across the cell lines. Thus, antibody 1 is
validated for Western blot analysis, unlike antibody 2, which is
not validated for this application. In Supplementary Table 2, a
summary of the results for all antibodies are shown and the
correlation results (Supplementary Table 3) are visualized in
Fig. 2c (blue bars). If a Pearson correlation cut-off of 0.5 is
considered across the cell panels, 46 of the antibodies pass the
validation criteria, while 7 antibodies have a correlation below 0.5.
Orthogonal validation of antibodies using transcriptomics. An
alternative to MS-based proteomics is to use transcriptomics
analysis as an orthogonal method (Fig. 2a). This approach is
based on the hypothesis that mRNA levels and corresponding
protein levels correlate at the steady state, which has been sug-
gested by several publications16–19. This method paves the way
for a relatively simple validation scheme for antibodies, since
transcriptome analysis of a set of reference cells and tissues
provides a data set that can be used in a proteome-wide manner.
Here, we generated transcriptomics data for all the cell lines used
in the validations described above. This enabled us to also use the
transcriptomics data for validation of the antibodies analyzed
above as shown for the examples in Fig. 2b. It is reassuring that
the validation of the two antibodies towards HNMT follows the
proteomics results with antibody 1 validated, in contrast to
antibody 2. A summary of the transcriptomics validation for all
53 antibodies is shown in Fig. 2c (purple bars) with 39 of these
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Fig. 2 Orthogonal validation of antibodies using proteomics. a Principle for the Western blot validation strategy based on correlating protein expression
levels determined across a panel of cell lines using either proteomics or transcriptomics. b Example of orthogonal validation of Western blot bands
(WB, relative intensity) by proteomics (Parallel Reaction Monitoring, PRM) reported as ratio to standard or transcriptomics reported as Transcript Per
Million (TPM). Error bars represent 1 s.d. across three technical replicates. The black arrow indicates the theoretical molecular weight of the protein and
blue arrows indicate the band subjected for the intensity-based relative quantiﬁcation to determine the antibody staining proﬁle. More examples including
loading controls are presented in Supplementary Fig. 2–3 for PRM and TMT, respectively. c Mirror plot summarizing the Pearson’s r for 53 antibodies
evaluated either by TMT (dark blue) or by PRM (light blue) including transcriptomics-based validation based on RNA expression (purple). d Analysis of the
Pearson’s r between Western blot band intensities and RNA expression levels as a consequence of the fold-change between the highest and lowest value
across the cell lines. The gray area represents fold-change in RNA levels less than ﬁvefold. Antibodies in the green area (Pearson’s r > 0.5) are considered
validated while antibodies in the red area (Pearson’s r < 0.5) are considered not validated
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antibodies passing using a Pearson correlation higher than 0.5
across all cell lines as cut-off.
To explore the correlation-based evaluation further, a scatter
plot (Fig. 2d) was generated displaying the dependence of
correlation as a result of RNA-level difference (log2 fold-change
between highest and lowest expression level). The same type of
plot showing the correlation as a function of difference in protein
levels for PRM and TMT can be found in Supplementary Fig. 4.
The plot (Fig. 2d) shows that six antibodies do not pass the
evaluation based on a cut-off of 0.5 despite a higher than ﬁvefold
difference in RNA levels across the cell lines. These were thus
scored as not validated for Western blot applications. The fold-
change in the RNA levels was less than ﬁvefold for eight
antibodies, resulting in a low correlation coefﬁcient, <0.5, despite
that they previously had been validated by proteomics. This
suggests that the RNA-based method requires relatively higher
variability of expression levels to achieve the required correlation
coefﬁcient. To further validate these antibodies, we performed a
genetic knockdown using gene-speciﬁc siRNA reagents in the cell
line U-2 OS for all antibodies evaluated using the TMT-based
proteomics analysis, including the set of 14 antibodies with less
than ﬁvefold change expression (Supplementary Fig. 2). The
results conﬁrm that the antibodies which had a low variability
and failed the transcriptomics-based method are indeed speciﬁc
for the protein target supporting the positive validation by the
proteomics methods.
In summary, the orthogonal methods allowed us to validate 46
of the 53 antibodies as speciﬁc for the target protein in the
Western blot assay, although six of the antibodies could not be
validated by the transcriptomics method, since the low expression
variability for these target proteins resulted in high statistical
noise and thus low formal correlation. The results demonstrate
the dependence on expression variability for correlation studies.
Orthogonal validation using a standardized assay. We next
decided to perform a systematic orthogonal validation based on
proteomics for antibodies used in the Human Protein Atlas
(www.proteinatlas.org) program, in which a standard assay using
two cell lines (RT4 and U-251) has been carried out. Since many
Western blots contain several bands, we decided to use the cri-
teria to only validate the strongest stained band in each case and
this band needed to be clearly separated from the weaker bands
(if present). In addition, as suggested above, we required a ﬁvefold
difference in RNA levels between the two cell lines for unam-
biguously allowing validation by the orthogonal method, but we
also allowed the antibody to be correlated if the expression levels
(trend) in the two cell lines supported the correlation and the
size of the band was conﬁrmed either by theoretical size estimate
or by the capture MS method described above. In Supplementary
Fig. 5 an example of an antibody towards AASS is shown sup-
ported by both the orthogonal methods (proteomics and tran-
scriptomics). Similarly, the stronger band for the antibody
towards SLC9A3R2 is validated using both orthogonal methods,
although a weaker band of higher molecular weight is present in
both cell lines. Using these criteria, 711 antibodies were validated
using the TMT proteomics data set (Supplementary Data 6).
Capture MS validation. An alternative proteomics-based method
for antibody validation is to use a virtual Western protocol as
outlined by Yang et al.14. This method is based on comparison
between the molecular weight of the stained band visualized by
the antibody against the protein size obtained by a capture MS
method in which multiple gel slices are cut out from the elec-
trophoretic separation and analysed separately by proteomics
(Fig. 3a). We decided to generate these virtual Western blots
using cell extracts from the two cell lines U-251 and RT4 used
in the standardized Western blot validation in the Human Pro-
tein Atlas effort. Protein extracts for these cell lines were indivi-
dually separated by SDS-PAGE in three technical replicates and
50 slices were excised for each lane, proteolytically digested by
trypsin and analyzed by shotgun proteomics. The peptides of
the target protein could thus be identiﬁed in the different gel
slices and general virtual Western blots could be generated cov-
ering a large part of the human proteome. In total, we identiﬁed
proteins towards 5,523 antibodies (Supplementary Data 7) in at
least one of the two cell lines allowing these antibodies to be
validated by the capture MS method. In Fig. 3b, an example of
such a comparison is shown with the size distribution of the
protein-speciﬁc peptides determined by the capture MS method
shown and a band of the expected size is conﬁrmed in both cell
lines based on gel migration.
Altogether, 3,650 antibodies generated within the Human
Protein Atlas effort were subsequently analyzed using the
orthogonal data from the capture MS approach and a summary
of the results are shown in Fig. 3c. In total, 2,888 (79%) of the
analyzed antibodies were shown to be supportive using the
capture MS approach (Supplementary Data 6). For approximately
half of these antibodies (n= 1,517), the antibody was also scored
as enhanced using at least one additional validation strategy.
The size estimates determined in both assays are relatively
crude and many proteins have similar molecular weights and
we therefore decided to analyze the theoretical molecular
weights of the entire human proteome as predicted from the
genome sequence (Fig. 3d, Supplementary Data 8). The results
show that for the human proteome, there is a maximum of
proteins with sizes around 50 kDa, corresponding to a length
of ~450 amino acids.
Independent antibody for validation. The independent antibody
strategy for antibody validation is based on comparison of the
staining pattern using two independent antibodies with no
overlapping epitopes. The same criteria as outlined above for
orthogonal validation was used and we have used the whole panel
of ﬁve samples from the standardized Human Protein Atlas
Western blot set-up with two cell lines (RT4 and U-251), one
sample of pooled human plasma and two tissue extracts (liver and
tonsil). Several examples of independent antibody validation are
shown in Supplementary Fig. 6 and altogether 1,922 antibodies
were validated using this method (Supplementary Data 6).
Genetic strategies for antibody validation. We subsequently
decided to use the genetic method for validation. The staining
of the antibody is evaluated by Western blot through analyses of
samples from cell lysates before and after knockdown of the
corresponding target gene. Here, we have compared the staining
of samples before and after knockdown of the target protein in
the human cell line U-2 OS by using two siRNA reagents speciﬁc
for the target gene. At least one of the reagents must result in a
down-regulation of more than 25% of the target protein. Several
examples are shown in Supplementary Fig. 7 and altogether 217
antibodies were validated using this method (Supplementary
Data 6).
Recombinant expression for validation of antibodies. Finally,
we used a recombinant expression strategy to over-express the
target proteins that in most cases were not expressed in the cell
lines used in the standard pipe-line. The staining of the antibody
is evaluated by Western blot through analyses of samples from
cell lysates with and without recombinant expression of the target
protein. Here, we have used recombinant expression in the
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human cell line HEK 293 and samples with and without
expression vectors have been analysed by Western blot. The
antibody must show a strong band in the cell line with recom-
binant expression and no or fainter band in the control. Several
examples of this validation method are shown in Supplementary
Fig. 8 and altogether 2,190 antibody targets were validated using
this method (Supplementary Data 6).
Summary of the enhanced validation of antibodies. The results
of the enhanced validation using the ﬁve strategies (Supplemen-
tary Table 4) are shown in Fig. 4a and summarized in Supple-
mentary Table 5 and individually listed in Supplementary Data 6.
Altogether 6,014 antibodies have been validated by at least one of
the enhanced validation strategies. Note that only orthogonal
validation using proteomics have been included in this summary.
A summary of 263 antibodies validated by three or more pillars is
shown in Fig. 4b and the validation in each pillar has been scored
as enhanced, uncertain or not done. The category uncertain
indicates that the particular validation strategy has been tried,
but the result of the validation is inconclusive, in most cases due
to the nature of the target protein. Many antibodies that show low
correlation in the orthogonal assay due to low variability of the
target protein and many antibodies in the capture MS assay fall
just outside boundaries of the expected band, which could be a
result of uncertainty in cutting out bands on a gel. Some anti-
bodies were scored as uncertain for the independent antibodies
validation and the lack of validation was in all cases due to the
non-speciﬁc staining of the paired antibody. For the genetic
method, some of the antibodies were scored uncertain and
although not proven, the lack of disappearance of a band in the
assay is most likely caused by failure of the siRNA reagents to
knockdown the target protein and thus due to technical issues
related to the genetic method, not the antibody speciﬁcity. Finally,
for the recombinant expression validation, only two antibodies
were scored as uncertain and, in both cases, this was due to the
lack of expression in the recombinant cell line.
Discussion
We show a path forward for systematic validation of antibodies
based on the ﬁve pillars proposed earlier11, but here adapted for
Western blot applications. The fact that each of the validation
pillars have limitations (Fig. 1) enforces the need for careful
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assessment of the most suitable strategy for a particular antibody.
Hence, the capture MS and the orthogonal methods are highly
suitable for streamlined efforts, since the underlying analysis
using mass spectrometry or transcriptomics can be performed in
advance in a centralized manner and the supporting data can
be shared through an open access policy. However, both methods
have limitation regarding speciﬁcity for some of the target pro-
teins in certain sample contexts. In contrast, independent anti-
bodies do not need any special reagents, clones or data from
additional methods, but since this method relies on knowledge of
the binding epitope of respective antibody, it cannot be used for
most antibodies available today. Genetic approaches based on
both CRISPR and siRNA are attractive and yield, in most cases,
easily interpreted results, but many proteins are essential for the
cell and these can therefore not easily be knocked down and most
validation efforts based on a genetic method only involves one
single cell line, which of course limits the broadness of the vali-
dation. It is also difﬁcult to use genetic methods for validation of
antibodies in human tissues and organs, limiting this validation
strategy for immunohistochemistry applications. Thus, many
antibodies can only be validated by a restricted number of the
ﬁve validation principles due to the inherited nature of the
target protein, i.e., similar expression level (excludes orthogonal
validation), no detectable peptides in proteomics (excludes
capture MS), lack of expression in the recombinant host (excludes
recombinant expression), or that the target protein is essential
for the cell (excludes genetic). In summary, antibodies towards
housekeeping proteins expressed at similar levels in all cells,
are well suited for validation using genetic and/or capture MS
strategies, while target proteins showing high variability in at
least two cells used for the validation, are well suited for ortho-
gonal and/or independent antibody strategy. In contrast, if the
target protein is not expressed at all in the panel of cells used for
the validation, it might be preferable to use the recombinant
expression strategy.
It is important to point out that although each of the ﬁve
enhanced validation principles provide evidence for speciﬁc
protein target binding by the antibody with no or little off-
target binding, this should not be understood as that the anti-
body will be speciﬁc in all sample contexts. The wording good
and bad antibody or the most speciﬁc antibody should be
avoided, since a speciﬁc antibody in one sample context can
give rise to high cross-reactivity in another sample context
depending on the nature of the epitope(s) that it will recognize.
The wording enhanced should thus be interpreted that the
antibody has been validated in a certain sample context by at
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least one of the pillars and it is therefore important that the
primary data describing the validation is provided in an open
access manner.
Here, many of the antibodies were classiﬁed as uncertain and
in most cases this was probably due to limitations of the vali-
dation assays for the respective target protein rather than the poor
performance of the antibody. This demonstrates the value of
using different independent validation methods without the need
of any prior knowledge of the target protein, and the data suggest
that the validation in one pillar yields enough comfort that the
antibody is speciﬁc for the target, although the addition of even
more validation pillars supports the speciﬁcity of the antibody
even further. We show that more than 6,000 antibodies published
on the Human Protein Atlas could be validated in this enhanced
manner using at least one of the ﬁve strategies presented here and
more than 1,600 of these antibodies were validated by at least two
of the pillars and 267 with three or more pillars (Fig. 4b). It is
important to point out that the staining of bands in Western blot
assays cannot be considered as strict quantitative. This means that
strict criteria for the stringency to consider an antibody validated
is not easy to deﬁne. It is therefore important to show the primary
data used for the validation enables users of a particular antibody
to review the supporting data. Here, all the underlying primary
data to support the enhanced validation score are published as
part of the antibody information page for respective antibody in
the Human Protein Atlas. In addition, we provide the capture
MS data for the two cell lines used here (RT4 and U-251). This
includes identiﬁcation and label-free quantiﬁcation of proteins
and their migration in the gel for 5,605 human target proteins.
This data can now be used by providers and users to validate
antibodies if these cell lines are used. Similarly, the tran-
scriptomics data for all cell lines used in any of the panels in this
work are publicly available in an open access manner to allow
providers and users to perform orthogonal validation of their
antibodies using these cell lines.
A convenient strategy for validation of antibodies is to use a
capture MS strategy based on identifying target protein peptides
in digested sections of the electrophoresis separation gel by mass
spectrometry and to compare the proteins’ migration to the
Western blot bands. An advantage of this method is that the
proteomics data only need to be generated once for a particular
cell line and the proteomics data for thousands of target protein
peptides for a selected cell line can be readily shared among
research groups in an open access manner (Supplementary
Data 9). This enables the use of data from a single shotgun
proteomics experiment to validate thousands of antibodies in
different laboratories. An additional strength of the method is
that it can prevent antibodies from being wrongfully rejected by
conﬁrming their migration pattern when this differs from the
target proteins’ theoretical molecular weight. However, we con-
sider the capture MS validation the weakest of the validation
pillars described here, due to the fact that many proteins are
migrating to the same region of the Western blot gel. The capture
MS validation is even more unreliable for mid-sized proteins of
molecular weight between 30 and 70 kDa emphasizing the need
for extra caution when analyzing Western blot bands in this size
interval, due to the added risk of off-target binding to unrelated
proteins of similar sizes.
One of the focuses in this work has been to introduce ortho-
gonal methods for validation of antibodies. This strategy opens
up streamlined efforts to validate antibodies using veriﬁed and
standardized cell or tissue lysate panels centrally obtained by
certiﬁed providers, in which the antibody-independent method is
performed and the data used for validation is provided and
shared in an open access manner. One of the issues of abundance
correlation is that cell lines with variable expression of the target
protein must be selected in the analysis. However, genome-wide
transcriptomics data is now available for thousands of cell lines
and this facilitates the selection of suitable cell lines for a parti-
cular protein target. Here, we show that the TMT proteomics
approach yields protein abundance data for 6,733 protein targets
using only two cell lines and similarly, the transcriptomics yields
essentially whole-genome expression data in a quantitative
manner for more than 14,000 protein-coding genes, thus enabling
validation of a large fraction of the protein-coding genome using
just a few selected cells or tissues. It is reassuring that all the
antibodies validated by the transcriptomics method were subse-
quently also validated by the orthogonal proteomics approaches
and/or the siRNA knockdown, suggesting that this method did
not generate false positives and thus makes it attractive for
streamlined validation efforts. A convenient systematic scheme
can thus be designed, suitable for analysis of a large fraction of the
human protein targets.
We show that all the validation strategies described here can be
used to investigate and validate antibodies that yield several bands
in the Western blot assay. This phenomenon is not uncommon
and could either be due to unspeciﬁc staining as a result of off-
target binding or speciﬁc staining of multiple isoforms of the
target protein due to proteolysis, post-translational modiﬁcations
or splice variants. The question arises if such an antibody should
be approved for Western blot application, provided that the off-
target band can be readily separated from the band corresponding
to the target protein. An important issue is thus how to annotate
and score these antibodies that have been validated by a two-
dimensional analysis combining size on the Western blot with
one of the validation strategies presented. Here, we decided to
allow the enhanced validation of antibodies with several bands
present, but only if the validated band is the most stained and that
it is clearly separated from any weaker band(s).
In summary, we show that the ﬁve pillars outlined in Fig. 1 can
be used to validate antibodies for Western blot applications in a
standardized and systematic manner. The methods described
here can also be used for other antibody-based methods, such as
immunohistochemistry, immunocytochemistry, ﬂow sorting, and
sandwich assays. Note that the validation must be performed in
an application-speciﬁc manner to ensure that the antibody vali-
dation is relevant for the sample treatment of each application. In
this context, it is important to point out that the use of a panel of
cell lines or tissues in the validation effort might not detect off-
target binding in other sample contexts. In many cases it might be
preferable to use a target-speciﬁc panel of tissues or cells to ensure
variability across the samples and thus making correlation studies
more accurate.
Methods
Production and quantiﬁcation of protein standards. DNA fragments were
initially cloned into the expression pAff8c20 and thereafter transformed into an
E. coli strain, auxotrophic for the amino acids arginine and lysine21, for recom-
binant protein production. Cells containing expression vectors were cultivated in
10 ml minimal media using 100 ml shake ﬂasks20. Heavy isotope-labeled (13C and
15N) versions of lysine and arginine (Cambridge Isotope Laboratories, Tewksbury,
MA, USA) were provided to the cells at 200 µg/ml to generate fully incorporated
heavy protein standards. Cell cultures were harvested and the QPrESTs were
puriﬁed using the N-terminal quantiﬁcation tag (Q-Tag), which included a
hexahistidine tag used for puriﬁcation by Immobilize Metal Afﬁnity Chromato-
graphy (IMAC). After puriﬁcation, all isotopic QPrEST fragments were absolutely
quantiﬁed by mass spectrometry against a non-labeled puriﬁed Q-Tag standard.
The Q-Tag standard, also including a C-terminal OneStrep-tag. This protein was
puriﬁed using IMAC chromatography and the IMAC elution buffer was exchanged
for 1 × PBS (10 mM NaP, 150 mM NaCl, pH 7.3) using a PD-10 desalting column
(GE Healthcare, Uppsala, Sweden). The sample was thereafter puriﬁed on a
StrepTrap HP column (GE Healthcare) on an ÄKTA Explorer system (GE
Healthcare) according to the manufactures protocol. All QPrEST fragments
were quantiﬁed by mixing 1:1 with Q-Tag-standard, which previously had been
quantiﬁed by amino acid analysis. The protein mixture was digested by trypsin by
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ﬁrst reducing the proteins with 10 mM dithiothreitol (DTT) for 30 min at 56 °C.
This was followed by addition of 50 mM iodoacetamide (IAA) and incubated in
dark for 20 min. Proteomics grade porcine trypsin (Sigma-Aldrich, St Louis, MO,
USA) was added in a 1:50 enzyme to substrate ratio and incubated in a thermo-
mixer at 37 °C. The reaction was quenched after 16 h by addition of formic acid
(FA) and the sample was desalted using in-house prepared StageTips packed with
C18 Bonded Silica matrix (3M Empore)22. Brieﬂy, three layers of Octadecyl
membrane were placed in 200 µl pipette tips. The membrane was activated by
addition of 100% acetonitrile (ACN), followed by centrifugation for 1 minute at
961 rcf. The membrane was equilibrated by addition of 0.1% FA, Milli-Q (MQ)
followed by centrifugation for 1 min at 931 rcf. The sample was acidiﬁed prior to
addition onto the membrane, followed by centrifugation for 1 min at 931 rcf. The
membrane was washed twice with 0.1% FA, MQ and the peptides were eluted in
two steps using 60% ACN, MQ. Desalted peptides were vacuum dried before
subjected for LC-MS/MS analysis.
Cell line cultivation used for targeted proteomics. Eight different cell lines
(A431, Hep G2, A549, HeLa, HEK 293, RT4, SH-SY5Y [available from DSMZ] and
U-2 OS [LGC/ATCC],) were cultivated at 37 °C in a humidiﬁed atmosphere
containing 5% CO2. A549 and SH-SY5Y were cultivated in Dulbecco’s modiﬁed
Eagle’s Medium (Sigma-Aldrich). HEK 293, HeLa and Hep G2 were cultivated in
Minimum Essential Medium Eagle (Sigma-Aldrich). U-2 OS and RT4 were culti-
vated in McCoy’s medium (Sigma-Aldrich) and A431 was cultivated in RPMI-1640
(Sigma-Aldrich). All media were supplemented with 10% Fetal Bovine Serum
(Sigma-Aldrich). Media for HEK 293, HeLa and Hep G2 were supplemented with
1% MEM non-essential Amino Acid Solution (Sigma-Aldrich) and media for and
Hep G2 were also supplemented with 1% L-Glutamine (Sigma-Aldrich). The cells
were cultivated up to 80% conﬂuence and cell numbers were counted with a
Scepter 2.0 Cell Counter (Merck Millipore, Billerica, MA, USA) before pellets were
collected and stored at −80 °C.
Cell lysis for targeted proteomics. Cells were dissolved in Lysis buffer (100 mM
Tris-HCl, 4% SDS, 10 mM DTT, pH 7.6) and incubated at 95 °C in a thermomixer
for 5 min at 600 rpm and thereafter sonicated at 50% amp (1 s pulse, 1 s hold) for
1 min. The same cell lysate was subjected for mass spectrometry analysis and
Western blot analysis.
Filter-aided sample preparation. One QPrEST mastermix was prepared to
represent endogenous levels of U-2 OS with light to heavy peptide ratios as close to
one as possible. The same amount of mastermix was spiked into cell lysates con-
sisting of one million cells. The lysate was diluted with denaturing buffer (8 M
Urea, 100 mM Tris-HCl, pH 8.5) and centrifuged through a 0.22 µm spin ﬁlter
(Corning, Corning, NY, USA). Trypsin digestion was performed using a previously
described ﬁlter-aided sample preparation (FASP) method23. Trypsin was added
in a 1:50 enzyme to substrate ratio and incubated overnight at 37 °C. Peptides
were extracted by solid-phase extraction using in-house prepared C18 StageTips
following the protocol described above. Desalted peptides were vacuum dried
before LC-MS analysis.
Liquid chromatography for targeted proteomics. Liquid chromatography was
performed using as Ultimate 3000 binary RS nano system (Thermo Scientiﬁc)
using an EASY-Spray ion source. All samples were stored in their lyophilized form
and were resuspended by the autosampler prior to injection as 1 µg sample material
was loaded onto an Acclaim PepMap 100 trap column (75 µm × 2 cm, C18, 3 µm,
100 Å), washed for 5 min at 0.250 µl/min with Solvent A (95% H2O, 5% DMSO,
0.1% FA) and thereafter separated using a PepMap 800 C18 column (15 cm ×
75 µm, 3 µm). The gradient went from Solvent A to Solvent B (90% ACN, 5% H2O,
5% DMSO, 0.1% FA) at a constant ﬂow of 0.250 µl/min, up to 43% Solvent B in
40 min, followed by an increase up to 55% in 10 min followed by a steep increase
to 100% B in 2 min. Online LC-MS was performed using a Q-Exactive HF mass
spectrometer (Thermo Scientiﬁc).
Spectral library generation for targeted proteomics. An equimolar pool of
QPrESTs (Supplementary Table 6) was digested by trypsin according to the in-
solution protocol described above. Only non-secreted protein targets were included
from a set of QPrEST sequences previously generated based on being frequently
identiﬁed in shotgun proteomics experiments performed on cell lines. The
recombinant protein sequences had to generate at least one proteotypic peptide
upon trypsin digestion. For initial screening, 50 fmol of each QPrEST was loaded
onto column and a Top5 MS method was performed with master scans at 60,000
resolution (mass range 300–1600 m/z, AGC 3e6), followed by ﬁve consecutive
MS/MS scans at 30,000 resolution (AGC 1e5, underﬁll ratio 0.1%) with normalized
collision energy set to 25. Raw mass spectrometry ﬁles were processed using
MaxQuant, using the search engine Andromeda and searched against a FASTA ﬁle
containing QPrEST sequences spiked into the E. coli proteome (BL21, Uniprot-ID:
#UP000002032), which was used for recombinant protein production Identiﬁed
peptides were further processed by only allowing proteotypic peptides mapping to
one single human gene (deﬁned by Swiss-Prot v72), thereby excluding peptides
with potential miscleavages and peptides including any methionine.
Data-independent MS acquisition targeted proteomics. Full MS master scans
at 60,000 resolution (mass range 300–1600 m/z, AGC 1e6) were followed by 20
data-independent acquisitions MS/MS at 60,000 resolution (AGC 1e6) deﬁned by a
scheduled Parallel Reaction Monitoring (PRM) method (Supplementary Data 10).
Precursors were isolated in a scheduled sequence with a 1.2 m/z isolation window
and the maximum injection time was set to 105 ms for both MS and MS/MS
resulting in a duty cycle of 2.7 s. The isolation list was split into two consecutive
LC-runs, targeting 120 paired light and heavy peptides per injection.
MS data evaluation and protein quantiﬁcation. Raw MS-ﬁles from the data-
independent method were processed using Skyline Proteomics Environment24.
The ratio between endogenous and heavy peptide standard was calculated from the
summed area intensity over retention time for each peptide fragment separately
(Supplementary Data 11). Median peptide ratios between replicates were used
to calculate the amount of peptide present in the cell lysate. When more than
one peptide per protein was available (12 proteins= 1 peptide, 14 proteins= 2
peptides, 2 proteins= 3 peptides, 1 protein= 4 peptides), the median peptide value
was used to determine the relative protein amount (Supplementary Data 4).
Western blot analysis I. Lysates representing the same number of cells,
approximately 15 µg of protein, from the cell lines A431, A549, HEK 293, U-2 OS,
Hep G2, HeLa, RT4, and SH-SY5Y subjected for PRM analysis were, together with
Precision Plus protein standard (Bio-Rad Laboratories, Hercules, CA, USA), loaded
on precast 4–20% Criterion TGX Precast Gels (Bio-Rad Laboratories) and run
under reducing conditions. Protein transfer to PVDF membranes was performed
using Trans-Blot Turbo Transfer system (Bio-Rad Laboratories) and the mem-
branes were blocked for 1 h at room temperature (RT) (5% dry milk, 0.5% Tween
20, TBS; 1 mM Tris-HCl, 0.15M NaCl). The membranes were incubated with
primary antibody (0.2 µg/ml) for 1 h at RT, followed by incubation with horse-
radish peroxidase (HRP)-conjugated antibody (swine anti-rabbit 1:4000, P0399,
Dako) for 45 min at RT. Detection and quantiﬁcation of the signal from the
chemiluminescence substrate (Immobilon Western Chemiluminescence HRP
Substrate, Merck Millipore) was made using a ChemiDoc XRS+ CCD camera and
the software Image Lab (Bio-Rad Laboratories). After detection, the membranes
were stripped using a protocol for mild stripping (Abcam, Cambridge, UK) and
blocked for 1 h. The membranes were incubated with anti-alpha tubulin antibody
(0.05 µg/ml, ab4074, Abcam) for 1 h at RT followed by incubation with HRP-
conjugated antibody and signal detection as above (Supplementary Data 5).
Western blot analysis II. In order to cover the standard HPA cell lines (RT4 and
U-251), four cell lines were replaced from Western blot analysis I. Approximately
15 μg of protein from the cell lines RT4, U-251, A549, Hep G2, U-2 OS, BJ, CACO-
2, and SK-MEL-30 subjected for TMT analysis were prepared by mixing with
reducing buffer (1.5 mg/ml lysate, Laemmli Sample Buffer (Bio-Rad Laboratories),
50 mM DTT) and heated to 95 °C for 5 min. The lysates were then loaded on a
precast 4–20% Criterion TGX Stain-Free Gel (Bio-Rad Laboratories) together with
PageRuler Plus Prestained Protein Ladder (Thermo Scientiﬁc), and run in Tris/
Glycine/SDS Electrophoresis Buffer (Bio-Rad Laboratories). The gel was imaged
using Stain-Free imaging with a ChemiDoc MP CCD camera and the Image Lab
software (Bio-Rad Laboratories). To ensure that the loaded amount of protein was
equal for all cell lines, the loading volume of each cell line was adjusted according
to the results from the Stain-Free gel imaging and new gels were run for membrane
production. Protein transfer to PVDF membranes was performed using the Trans-
Blot Turbo Transfer system as described by the manufacturer (Bio-Rad Labora-
tories) and the membranes were blocked for 1 h at RT (5% dry milk, 0.1% Tween
20, TBS; 10 mM Tris, 0.15M NaCl). The membranes were incubated with primary
antibody (0.4 μg/ml) for 1 h at RT, followed by washing in TBS (1 × 5 min) and
incubation with HRP-conjugated antibody (swine anti-rabbit 1:3000, P0399, Dako)
for 45 min at RT. After additional wash with TBS (3 × 5 min) detection and sub-
sequent quantiﬁcation of the signal (Immobilon Western Chemiluminescence HRP
Substrate, Merck Millipore) was performed using a ChemiDoc MP CCD camera
and the Image Lab software (Bio-Rad Laboratories). To verify equal loading, the
membranes were thereafter incubated with an anti-PSMA1 antibody (Supple-
mentary Fig. 9), which served as an internal standard (0.3 μg/ml, HPA037646) and
HRP-conjugated antibody (swine anti-rabbit 1:3000, P0399, Dako) mixture for 1 h
at RT followed by signal detection as above (Supplementary Data 5).
Cell line cultivation for TMT quantiﬁcation and capture MS. A549 and BJ cells
were grown in Dulbecco’s modiﬁed Eagle medium (DMEM; Invitrogen, Carlsbad,
CA) supplemented with 10% FBS and 1% streptomycin. SK-MEL-24 cells were
grown in EMEM supplemented with 15% FBS and 1% streptomycin. CACO-2, Hep
G2, SK-MEL-28 and U-251 were grown in EMEM supplemented with 10% FBS
and 1% streptomycin. RT4 and U-2 OS were grown in McCoy supplemented with
10% FBS and 1% streptomycin.
Cell lysis for TMT quantiﬁcation and capture MS. Cells were lysed in lysis buffer
(1% SDC in 1× PBS supplemented with 1 mM sodium orthovanadate, 1 tablet of
Complete mini EDTA‐free mixture (Roche Applied Science) and one tablet of
PhosSTOP phosphatase inhibitor mixture (Roche Applied Science) per 10 ml of
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lysis buffer) by heating at 95 °C for 10 min. Cells were further lysed by 10 rapid
passages through a 23‐gauge hypodermic syringe needle and by sonication on ice.
After centrifugation (20,000 × g, 30 min at 4 °C), the protein concentration was
determined by BCA (Pierce).
Sample preparation for capture MS. Protein lysates from the two cell lines (RT4
and U-251) were prepared in Laemmli Sample Buffer (BioRad Laboratories, 50 mM
DTT) to a concentration of 1.5 mg protein per ml lysate and heated to 95 °C
for 5 min. Approximately 45 µg of protein was loaded, in triplicates, on a precast
4–20% Criterion TGX StainFree Gel (BioRad Laboratories), together with
PageRuler Plus Prestained Protein Ladder (Thermo Scientiﬁc), and run according
to the manufacturer’s recommendation. The gel was rinsed in water (3 × 5 min),
stained using GelCode Blue Stain Reagent (Thermo Scientiﬁc) for 1 h and
destained through washing in water (2 × 1 h). Lanes were excised in bands
according to Supplementary Fig. 10. The in-gel digestion was performed as pre-
viously described25 with some changes to the original protocol as outlined below.
Brieﬂy, gel pieces were shrunk in 100% ACN and reduced by 10 mM DTT for
30 min at 56 °C. Alkylation was performed by addition of 55 mM 2-
choloroacetamide and incubated in dark for 20 min. Trypsin digestion was per-
formed over night at 37 °C after addition of trypsin (13 ng/µl in 50 mM ammonium
bicarbonate, 10% ACN (vol/vol)). Peptides were extracted by addition of 100 µl of
extraction buffer (1:2 (vol/vol) 5% formic acid/ACN) and dried down by vacuum
centrifugation prior to LC-MS/MS analysis.
LC-MS/MS analysis of gel pieces. Each sample was analyzed on a Bruker Impact
II (Bruker Daltonics, Germany) connected to a Dionex UHPLC system (Thermo
Fisher Scientiﬁc). The UHPLC was equipped with a trap column (Acclaim PepMap
100, 75 μm× 2 cm, nanoviper, C18, 3 μm, 100 Å; Thermo Fisher Scientiﬁc) and an
analytical column (PepMap RSLC C18, 2 μm, 100 Å, 75 μm× 50 cm; Thermo Fisher
Scientiﬁc). Mobile‐phase buffers for nLC separation consisted of 5% ACN/0.1% FA
in water (solvent A) and 95% ACN/0.1% FA (solvent B). The peptides were eluted
during a 2 h gradient and directly sprayed into the mass spectrometer. The ﬂow
rate was set at 400 nl/min, and the LC gradient was as follows: 4% solvent B within
5 min, 4–32% solvent B within 90 min, 32–95% solvent B within 1 min, 100% B for
10 min and down to 2% solvent B within 1 min following equilibration at 2%
solvent B for 13 min. Nano spray was achieved with an applied voltage of 1.6 kV
using a Captive Spray source (Bruker Daltonics, Germany) connected to a
NanoBooster ﬁlled with 100% ACN. The mass spectrometer was programmed in a
data‐dependent acquisition mode (cycle time set to 3 s) and was conﬁgured to
perform a survey scan from 150 to 2200 m/z (1 Hz). MS2 scans were acquired in
dynamic mode (2500 cts= 8 Hz to 25,000 cts= 32 Hz) of ions with charge state
between 2 and 5 with a smart exclusion (5×) set to 30 s.
Data analysis of capture MS. Intensities for label-free MS quantiﬁcation was
performed by analyzing the raw data by MaxQuant (version 1.5.7.0)26. Andro-
meda27 was used to search the MS/MS data against the Ensembl Homo sapiens
database (version 88.38, using all protein-coding transcripts from the primary
assembly) complemented with a list of common contaminants and concatenated
with the reversed version of all sequences. Trypsin/P was chosen as cleavage
speciﬁcity allowing two missed cleavages. Carbamidomethylation (C) was set as a
ﬁxed modiﬁcation, while oxidation (M) was used as variable modiﬁcation. Data
ﬁltering was carried out using the following parameters: peptide and protein FDRs
were set to 1%, minimum peptide length was set to 7. The reverse and common
contaminant hits were removed from the MaxQuant output.
Protein digestion prior to TMT labeling. Proteins were reduced with 2 mM DTT
at RT for 1 h, alkylated with 4 mM 2-chloroacetamide at RT for 30 min in the. A
ﬁrst enzymatic digestion step was performed Lys-C at 37 °C O.N. (1:50 w/w). Each
sample was diluted ten times and digested with trypsin O.N. (1:50 w/w). The
resulting peptides of each cell line were chemically by TMT10plex according to the
manufacturer’s instructions: Reference Pool (126); SK-MEL-24 (127 N); SK-MEL-
28 (127 C); U-2 OS (128 N); A549 (128 C); U-251 (129 N); BJ (129 C); RT4
(130 N); Hep G2 (130 C); CACO-2 (131). Samples were mixed 1:1 and desalted
using Sep‐Pak Vac C18 cartridge (1 cc/200 mg, Waters), and the eluted peptides
were dried down and stored at −20 °C. The same procedure was repeated for the
other two biological replicates.
Basic reverse phase fractionation. Two hundred μg of peptide mixture from each
set were fractionated using a Waters XBridge BEH300 C18 3.5 μm 2.1 × 250 mm
column on an Agilent 1200 series operating at 200 μl/min. Buffer A consisted of
20 mM NH3, while buffer B of 80% ACN/20 mM NH3. The fractionation gradient
was: 3–88% B in 63 min; 88% B for 15 min; and ramped to 100% B in 2.5 min;
100% B for 13.5 min. Fractions were collected into polypropylene V-96 well
microtiter plates (Microplate, 96 well PP, V-Bottom; Grainer BIO-ONE). At
97 min, fraction collection was halted, and the gradient was held at 3% B for
20 min. The total number of concatenated fractions was set to 12. Each plate was
dried at RT using a Speed Vac (SPD 111 V, Thermo). Plates were stored at −20 °C
till LC-MS/MS analysis.
LC-MS/MS analysis of TMT-labeled samples. Each sample was analyzed on a
HF Q-Exactive Orbitrap (Thermo Fisher, Germany) connected to a Dionex
UHPLC system (Thermo Fisher Scientiﬁc). The UHPLC was equipped with a trap
column (Acclaim PepMap 100, 75 μm× 2 cm, nanoviper, C18, 3 μm, 100 Å;
Thermo Fisher Scientiﬁc) and an analytical column (PepMap RSLC C18, 2 μm,
100 Å, 75 μm× 50 cm; Thermo Fisher Scientiﬁc). Mobile‐phase buffers for nLC
separation consisted of 0.1% FA in water (solvent A) and 80% ACN/0.1% FA
(solvent B). The peptides were eluted during a 2 h gradient and directly sprayed
into the mass spectrometer. The ﬂow rate was set at 250 nl/min, and the LC
gradient was as follows: 3–6% solvent B within 3 min, 6–35% solvent B within
117 min, 35–47% solvent B within 5 min, 47–100% solvent B within 5 min and
100% B for 8 min and 1% solvent B for 5 min. Nano spray was achieved with
an applied voltage of 1.8 kV. The mass spectrometer was programmed in a data‐
dependent acquisition mode (top 10 most intense peaks) and was conﬁgured to
perform a Fourier transform survey scan from 370 to 1600 m/z (resolution 60,000),
AGC target 3e6, maximum injection time 250 ms. MS2 scans were acquired on the
10 most-abundant MS1 ions of charge state 2–7 using a Quadrupole isolation
window of 1 m/z for HCD fragmentation. The collision energy was set at 34%;
resolution= 30,000; AGC target 2 e5, maximum injection time 200 ms; dynamic
exclusion 15 s.
Data analysis. TMT10plex quantiﬁcation was performed by analyzing the raw
data by MaxQuant (version 1.5.3.30)26. Andromeda27 was used to search the
MS/MS data against the UniProt Homo sapiens database (containing canonical and
isoforms_42144 entries downloaded on 21 March 2016) complemented with a list
of common contaminants and concatenated with the reversed version of all
sequences. Trypsin/P was chosen as cleavage speciﬁcity allowing two missed
cleavages. Carbamidomethylation (C) was set as a ﬁxed modiﬁcation, while
oxidation (M) was used as variable modiﬁcation. Data ﬁltering was carried out
using the following parameters: peptide and protein FDRs were set to 1%,
minimum peptide length was set to 7. The reverse and common contaminant hits
were removed from MaxQuant output. Samples were normalized to the median
intensity for each TMT channel respectively after removing CON and REV protein
sequences (Supplementary Data 9). Protein values used for orthogonal validation
were calculated across triplicate LC-MS/MS measurements and reported as the
median protein intensity (Supplementary Data 3).
Transcriptomics analysis. Procedures for extraction of RNA, library preparation,
and sequencing has been described elsewhere29. Reads were mapped to the human
reference genome assembly GRCh38 and quantiﬁed by Kallisto version 0.42.430.
Normalized expression levels (TPM values) on gene level were obtained by
summing the estimated values from the constituent transcripts of each gene,
respectively.
Data availability
The TMT10plex data have been deposited to the ProteomeXchange Consortium (http://
proteomecentral.proteomexchange.org) via the PRIDE partner repository28 with the data
set identiﬁer PXD005914. The Capture MS LC-MS/MS data can be accessed using the
PXD010178 identiﬁer. Chromatograms used for the targeted proteomics quantiﬁcation
are made available through Panorama (https://panoramaweb.org/western_blot.url)
and the corresponding raw data are available through Chorus (chorusproject.org),
experimental ID 1213. All cell line data from transcriptomics analysis are available at
http://www.ncbi.nlm.nih.gov/bioproject/PRJNA183192. All cell line data are available
at http://www.ncbi.nlm.nih.gov/bioproject/PRJNA183192.
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